

Crystal structure of obelin after Ca^{2+} -triggered bioluminescence suggests neutral coelenteramide as the primary excited state

Zhi-Jie Liu^{*†}, Galina A. Stepanyuk^{**}, Eugene S. Vysotski^{**}, John Lee^{*§}, Svetlana V. Markova[‡], Natalia P. Malikova[‡], and Bi-Cheng Wang^{*}

^{*}Department of Biochemistry and Molecular Biology, University of Georgia, Athens, GA 30602; [†]Institute of Biophysics, Chinese Academy of Sciences, 15 Datun Road, Beijing 100101, China; and [‡]Photobiology Laboratory, Institute of Biophysics, Russian Academy of Sciences, Siberian Branch, Krasnoyarsk 660036, Russia

Communicated by J. Woodland Hastings, Harvard University, Cambridge, MA, December 23, 2005 (received for review November 10, 2005)

The crystal structure at 1.93-Å resolution is determined for the Ca^{2+} -discharged obelin containing three bound calcium ions as well as the product of the bioluminescence reaction, coelenteramide. This finding extends the series of available spatial structures of the ligand-dependent conformations of the protein to four, the obelin itself, and those after the bioluminescence reaction with or without bound Ca^{2+} and/or coelenteramide. Among these structures, global conformational changes are small, typical of the class of "calcium signal modulators" within the EF-hand protein superfamily. Nevertheless, in the active site there are significant repositions of two residues. The His-175 imidazole ring flips becoming almost perpendicular to the original orientation corroborating the crucial importance of this residue for triggering bioluminescence. Tyr-138 hydrogen bonded to the coelenterazine N1-atom in unreacted obelin is moved away from the binding cavity after reaction. However, this Tyr is displaced by a water molecule from within the cavity, which now forms a hydrogen bond to the same atom, the amide N of coelenteramide. From this observation, a reaction scheme is proposed that would result in the neutral coelenteramide as the primary excited state product in photoprotein bioluminescence. From such a higher energy state it is now energetically feasible to account for the shorter wavelength bioluminescence spectra obtained from some photoprotein mutants or to populate the lower energy state of the phenolate anion to yield the blue bioluminescence ordinarily observed from native photoproteins.

coelenterazine | photoprotein | EF hand | luciferase | aequorin

Among several luciferins that have been identified in luminous organisms, one well characterized type is "coelenterazine," an imidazopyrazinone derivative. The best studied proteins using this luciferin are the Ca^{2+} -regulated photoproteins such as those responsible for the bioluminescence of marine coelenterates (1), for example, aequorin from the jellyfish *Aequorea* (2, 3) and obelin from the hydroid *Obelia* (4, 5). All of the photoproteins characterized to date consist of a single polypeptide chain with high sequence homology and contain three "EF-hand" Ca^{2+} -binding consensus sequences (6–8) like some other Ca^{2+} -binding proteins (9). Their bioluminescence property derives from the fact that they contain in their active site an "activated" coelenterazine, 2-hydroperoxycoelenterazine, tightly but noncovalently bound. Thus, photoproteins can be regarded as luciferases except that they have a high energy reaction intermediate frozen in place (10). The binding of Ca^{2+} into the loops of the EF-hands apparently leads to some conformational change in the photoprotein that destabilizes this intermediate leading to rapid emission of bioluminescence. This response on the millisecond time scale must have to do with the biological function in the animal, e.g., frightening of predators, although this function is not established.

It is the purpose of our structural studies to determine how the Ca^{2+} binding triggers the destabilization of the intermediate and

how interactions with the residues comprising the active site direct the decarboxylation of the peroxycoelenterazine to efficiently produce the protein bound product, coelenteramide, in its excited (fluorescent) state (11, 12). The blue bioluminescence emission results when this excited coelenteramide relaxes to its ground state. The bioluminescence spectra are broad with maxima in the range 465–495 nm depending on the type of photoprotein (13). Spatial structures recently determined for aequorin and obelin confirm the presence of this 2-hydroperoxycoelenterazine and show that it is situated within a hydrophobic cavity and stabilized there by a hydrogen bond network (14, 15).

In this paper, we report the crystal structure at 1.93 Å of Ca^{2+} -discharged obelin, i.e., obelin after the addition of Ca^{2+} to generate bioluminescence with both bound coelenteramide product and three calcium ions (state III, Fig. 1). This result now extends the series of available crystal structures of the ligand-dependent conformations of obelin to four (16) (Fig. 1). This structure shows important differences in how some residues are arranged in the binding cavity compared to the previously determined Ca^{2+} -discharged obelin that lacked the bound Ca^{2+} (state IV, Fig. 1) and leads to a suggestion for a pathway forming coelenteramide in its neutral excited state as the primary product of this bioluminescence reaction.

It should be noted that comparable structural insight into photoprotein bioluminescence is not available from the structures of other types of luciferases (19–21) and indeed, there are few other enzymes available with substrate or product able to be visualized within the active site. Many of the EF-hand family of calcium proteins exert their biological function via interactions usually with macromolecular ligands and structural determinations of these complexes is an active area of research (22).

Results

Overall Structure. The spatial structure of the protein retains the same overall scaffold with its characteristic two-domain fold (Fig. 2A), in all conformation states (Fig. 2B and Table 1). The range of overall main chain rms deviations is only from a minimum 1.922 Å (between conformation states II and III) to a maximum 2.077 Å (between states III and V). Additionally, the C-terminal domain undergoes a bigger change than the N-terminal domain. EF-hand ii in the N-terminal domain does not have the loop consensus sequence for binding Ca^{2+} and therefore shows no significant change in any of the confor-

Conflict of interest statement: No conflicts declared.

Abbreviation: PDB, Protein Data Bank.

Data deposition: The crystal structure reported in this paper has been deposited in the Protein Data Bank, www.pdb.org (PDB ID code 2F8P).

[§]To whom correspondence should be addressed. E-mail: jlee@bmb.uga.edu.

© 2006 by The National Academy of Sciences of the USA




Fig. 1. The three-dimensional structures of conformation states of obelin: II, obelin with 2-hydroperoxycoelenterazine in the absence of Ca^{2+} (PDB ID code 1EL4) (15); III, Ca^{2+} -discharged obelin with both coelenteramide and bound Ca^{2+} (present result); IV, Ca^{2+} -discharged obelin with coelenteramide but without Ca^{2+} (PDB ID code 1S36) (17); V, Ca^{2+} -loaded apo-obelin (PDB ID code 1SL7) (18). The structure of apo-obelin (state I) is not determined. The crystal structures of different obelin conformation states are presented in the same orientation. The 2-hydroperoxycoelenterazine and coelenteramide molecules are displayed by the stick models in the center of the protein; the calcium ions are shown as red balls.

mation states. However, rms deviations of side chain atoms are much bigger (Table 1). The largest repositioning of atoms is observed again in the C-terminal domain and EF-hand iv.

Table 1. rms deviation values of state III vs. different obelin states

rms deviation*	State II	State IV	State V
Overall†	1.922/2.745‡	1.996/2.783	2.077/3.274
N-terminal domain§	1.342/2.012	1.349/1.979	0.958/2.069
C-terminal domain¶	1.969/3.164	1.978/3.181	2.652/4.225
EF-hand ii	1.685/2.283	1.701/1.937	0.826/1.924
EF-hand iii	0.463/1.536	0.589/1.925	0.472/1.767
EF-hand iv	1.818/3.094	1.801/3.015	1.524/3.247
EF-hand v	1.839/3.350	1.876/3.446	1.763/3.738
Loop i**	1.119/1.948	0.735/1.371	0.180/0.919
Loop ii	0.455/1.866	0.444/1.889	0.275/0.488
Loop iii	1.404/2.574	—††	0.598/0.814
Loop iv	1.905/4.632	1.912/4.586	0.721/0.838

*rms deviation was calculated using the program LSQKAB(W 1976).

†The conformational flexible residues 1–10 were excluded in the calculation to better reveal the effect of conformation changes caused by calcium binding and coelenterazine decarboxylation.

‡rms deviation values of main chain/side chain atoms.

§Residues 11–106.

¶Residues 107 to C terminus.

**EF-hands i, ii, iii, and iv are defined as residues 17–54, 58–104, 110–141, and 149–180, respectively.

***Loops i, ii, iii, and iv are defined as residues 30–40, 75–85, 123–133, and 158–168, respectively.

††Loop iii is disordered in this crystal structure.

Also, the side chain atoms of loop iv undergo the biggest repositioning even among loops capable of binding Ca^{2+} . A calcium atom is found at each of the expected Ca^{2+} -binding sites, EF-hand loops i, iii, and iv, as also observed in state V, the Ca^{2+} -loaded apo-obelin (18).

In obelin (Fig. 2A), as in aequorin, the C terminus caps the substrate cavity providing a solvent-inaccessible and nonpolar




Fig. 2. The spatial structure of Ca^{2+} -discharged obelin and its comparison with other ligand-dependent conformation states shown in Fig. 1. (A) Stereoview of the overall crystal structure of Ca^{2+} -discharged obelin. The stick model in the center of the protein is the coelenteramide molecule. The helices are marked by capital letters A–H. Numbers i–iv designate the loops. Calcium ions are shown as red balls. (B) Stereoview of the superimposition of different obelin conformation states: II, blue; III, brown; IV, pink; and V, green. The 2-hydroperoxycoelenterazine and coelenteramide molecules are displayed by the stick models in the center of the protein; the calcium ions are shown as balls. The 2-hydroperoxycoelenterazine, coelenteramide, and calcium are colored according to the conformation state. (C) Sequence of the obelin from *O. longissima* (45). The residues comprising the coelenteramide binding cavity or participating in calcium binding are marked with red and blue, respectively. The helices and loops involved in the binding of Ca^{2+} are shown as brown and gray cylinders, respectively, according to the structure of Ca^{2+} -discharged obelin.




Fig. 3. Stereoview of the superposition of Ca^{2+} -binding loop iv of obelin in the Ca^{2+} -discharged state (green) (III) and the native state (gray) (II). The calcium ion and the water molecule are shown as pink and blue balls respectively.

environment. This condition apparently optimizes the efficient population of the first electronic excited state of the product coelenteramide and favors a high quantum yield for its fluorescence (23). The inaccessibility of the substrate for solvent occurs as a result of the numerous hydrogen bond interactions of residues situated in helix A with residues from helix H and from others in the C terminus. For instance, in obelin (state II) the $\text{N}_{\epsilon 2}$ atoms of His-22 and His-24 (helix A) form hydrogen bonds with carbonyl oxygens of Trp-179 (helix H) and Gly-193 (C terminus); $\text{N}_{\eta 1}$ and $\text{N}_{\eta 2}$ atoms of Arg-21 (helix A) are hydrogen bonded with the carbonyl oxygen of Phe-178 (helix H), with the $\text{O}_{\delta 1}$ oxygen of Asp-187 (C terminus), and with the oxygen of Pro-195, all situated in the C terminus. All these listed hydrogen bonds persist in the Ca^{2+} -discharged obelin having bound coelenteramide and calcium (state III) and this strengthens the idea that the binding cavity remains inaccessible for solvent, thus providing the environment favoring the efficient fluorescence of the bound coelenteramide in the Ca^{2+} -discharged photoproteins (8, 24).

Ca^{2+} -Binding Loops. For binding Ca^{2+} into the EF-hand, the 12 residues of the loop shift their positions to accommodate the Ca^{2+} in its preferred configuration. Fig. 3 illustrates this movement for the case of loop iv. Loops i and iii have similar but lesser adjustments (Table 1). The typical geometrical arrangement of oxygen atoms in a pentagonal bipyramid is observed with the Ca^{2+} occupying the center of the pyramid. All three Ca^{2+} -binding sites of obelin contribute six oxygen ligands to the metal ion, derived from the carboxylic side groups of Asp and Glu residues, the carbonyl groups of the peptide backbone, or the side chain of Asn, and the hydroxyl group of Ser, all with a coordination distance of ≈ 2.4 Å. The seventh ligand comes from the oxygen of a water molecule. Based on studies of the EF-hand Ca^{2+} -binding proteins from different sources, it has been observed that high-affinity Ca^{2+} -binding sites have either no water or at most one water ligand (25). The three Ca^{2+} -binding sites of the Ca^{2+} -discharged obelin each contain only one water molecule as a ligand, indicating that they all can have high affinity for calcium. Fig. 3 also shows how the loop residue shifts propagate along the chain to reorientate His-175. This displacement of His-175 is postulated as the trigger of the bioluminescence reaction (13).

Structure of the Coelenteramide Binding Cavity. The coelenteramide is situated at the center of this protein structure in the place occupied by the substrate coelenterazine in obelin. The residues comprising the binding cavity, i.e., within 4 Å of the coelenter-




Fig. 4. Stereoview of the superposition of 2-hydroperoxycoelenterazine (green) from PDB ID code 1QV0 and coelenteramide (brown) from present structure, with the key residues facing into the binding cavity. Water molecules are shown as balls.

amide, are indicated in red in Fig. 2C. After the bioluminescence discharge, most residues essentially remain in place compared to their location in the obelin cavity except Ile-142, Ile-111, Phe-119, Ile-142, Ile-144, Trp-135, and Tyr-138, which are displaced, and Phe-28, Gly-143, and Thr-172, which move into the cavity. On average, the residues moving into the cavity are more polar than those that are displaced. As in obelin, there are two water molecules in the cavity of the discharged protein but they are repositioned and for one of them, W_2 , this appears to have mechanistic significance.

Aside from the loss of CO_2 from the chemical decomposition of coelenterazine, the biggest change in its molecular structure is in the reaction center around the C-2 position (C-2, O-33, and C-10) and C-8, resulting in an obvious orientational deviation of the phenol group at the C-10 position and the phenyl group at the C-8 (Fig. 4). Other parts of the molecule also adjust positions a little, but not dramatically. His-22 and Trp-92, which were in hydrogen bond distances with the oxygen of the 6-(*p*-hydroxyphenyl) group of coelenterazine before reaction (Fig. 5A), are at practically the same distances to coelenteramide in the product cavity. The N_{ϵ} atoms of these residues are at 2.74 Å and 3.07 Å from the oxygen atom of the 5-(*p*-hydroxyphenyl) group of coelenteramide, indicative of moderate hydrogen bond interactions (Fig. 5B). In obelin, the N_{ϵ} atom of Trp-179 is 3.32 Å from the C3-carbonyl oxygen (Fig. 5A) but after reaction, this residue is moved in the direction of Tyr-190 with formation of a new hydrogen bond to it. The Tyr-190 OH group, which apparently stabilizes the 2-hydroperoxy group of coelenterazine in obelin by a hydrogen bond and is also hydrogen bonded to His-175, is also slightly repositioned in the Ca^{2+} -discharged protein. The hydrogen bond to His-175 is lost but a new hydrogen bond develops to the carbonyl of coelenteramide. There is a major reorientation of the His-175 with its imidazole ring now almost perpendicular to the original orientation (Fig. 4). His-175 also forms new hydrogen bonds with the N1 atom of coelenteramide and the water molecule W_1 (Fig. 5B). Tyr-138 is moved out of the binding cavity (Fig. 4). The hydrogen bond from Tyr-138 originally to the N1 of coelenterazine now goes to Glu-55 (Fig. 5B), and the Tyr-138 appears to be replaced by that water molecule (W_2) originally connecting Tyr-138 to His-64 (Fig. 5A). As a result, the His-64 is also slightly shifted toward coelenteramide. The second water molecule (W_1) is also moved, apparently after the change in position of the 2-(*p*-hydroxybenzyl) group.

Thus, only His-175 and Tyr-138 undergo a noticeable repositioning in the binding cavity after the bioluminescence reaction. The importance of the His residue in this position for photoprotein bioluminescence was demonstrated with aequorin (26). Substitution of His-169 (His-175 in obelin) resulted in loss of bioluminescent activity. In contrast, Tyr-138 is not absolutely

moved into position at this point, but this cannot be verified easily because the protein with dioxetanone and calcium bound would be technically difficult to trap and prepare for crystal structure analysis. However, because Tyr-138 is not essential for the bioluminescence as shown by its substitution to Phe, this assumption is reasonable.

Because the pK of the amide is likely to be higher than the water molecule in this environment, protonation of the anion from the proximate water molecule (Scheme 1, step 3) would be rapid and lead to the neutral dioxetanone. This would be made more energetically feasible by a proton relay from His-64 if that histidine was in its protonated state. We propose that the critical function of this specific water molecule here is to catalyze the decarboxylation reaction by protonating the dioxetanone anion (step 3). Step 4 in Scheme 1 then yields the neutral coelenteramide as the primary excited product in the bioluminescence.

Scheme 1 would rationalize many properties peculiar to coelenterazine bioluminescence *in vitro*. Both luciferase and photoprotein systems have *in vitro* bioluminescence spectral maxima in the range of 460–495 nm. A similar range is observed for the fluorescence of coelenteramide analogs in solvents of varying polarity and the presence of strong base and therefore is attributed as originating from the excited state of the coelenteramide anion (29, 30). However, in some mutants of both aequorin and obelin (31–34) two bioluminescence bands can be generated, one similar to the wild type and the other at higher energy with a maximum of ≈ 400 nm. This latter value corresponds to the fluorescence from the neutral state of coelenteramide. In many studies of these bioluminescence systems, it is stated that the excited coelenteramide anion is the primary excited state product. This belief arises from earlier reports such as by McCapra and Chang (35), who investigated the chemiluminescence of an imidazopyrazinone derivative in an aprotic solvent with strong base and provided convincing evidence for a coelenteramide anion as the primary excited state. However, in photoprotein bioluminescence, if the coelenteramide anion were the primary excited state product, it would be energetically infeasible for it to populate the neutral excited state at higher energy. Scheme 1 therefore provides a pathway for formation of the neutral excited state as the primary product. For coelenterazine having the dissociable 6-(*p*-hydroxyphenyl) group, the longer wavelength bioluminescence bands arise from the excited phenolate after excited state proton transfer to His-22. This process has been described (13).

There is now a sufficient collection of Ca²⁺-regulated photoprotein structures to conclude that all have a similar cavity structure and should operate by the same mechanism as in Scheme 1. Although there are differences in spectral properties among them, it has been already demonstrated that these are due to different interactions of the coelenteramide with the side chains of residues making up the binding cavity (32, 36). Kinetic properties, Ca²⁺ sensitivity, thermostability, and so on, are much more difficult to account for, in common with trying to account for enzymatic properties from structural information in general.

Coelenterazine is widely used as a bioluminescent substrate. In addition to Ca²⁺-regulated photoproteins, this same molecule has been identified as the luciferin for *Renilla* luciferase from the soft coral *Renilla* (37) and for the luciferases from copepods (38) as well as for luciferases from some other organisms (the deep-sea shrimp *Oplophorus*, the scyphozoan medusa *Periphylla*, etc.). The spatial structures of coelenterazine-type luciferases are not yet available and only a few sequences are in hand, but already these data indicate that luciferase overall structures will differ from the photoproteins. In addition, the luciferases are not Ca²⁺-dependent proteins, but the bioluminescence properties and the overall chemistry appear to be common with the photoproteins. From the spectral data, we predict a consensus property to be the arrangement of luciferase binding site residues

Table 2. Summary of crystallographic statistics

Statistics	Value
Data processing	
Resolution range (Å)	50.00–1.93 (2.00–1.93)
Wavelength, Å	0.9725
Space group	P4 ₃
Cell dimensions, Å	<i>a</i> = 64.26, <i>c</i> = 63.05
Unique reflections	16,980 (875)
Completeness (%)	86.7 (41.2)
<i>I</i> / σ (<i>I</i>)	26.22 (2.54)
<i>R</i> _{sym} (%)	7.5 (30.0)
Redundancy	5.2 (1.8)
Refinement	
Resolution range, Å	50.00–1.93
Reflections used (free)	16,136 (844)
<i>R</i> _{work} (<i>R</i> _{free})	17.1% (21.3%)
Mean B factor (Å ²)	28.5 (27.4)
Protein atoms (solvent)	1561 (139)
RMSD bond lengths, Å	0.016
RMSD bond angles, °	1.532

hydrogen bonded to the *p*-hydroxy group of the 6-substituent of coelenterazine, corresponding to Trp-92 and His-22 in obelin. For the luciferases, there should be a different hydrogen bond network around the C2–C3 atoms of coelenterazine, one that favors the oxygen peroxidation of coelenterazine and then its decarboxylation, rather than stabilization of the hydroperoxide as in the photoproteins.

Materials and Methods

Protein Sample. The high purity obelin was produced as reported (15). The Ca²⁺-discharged obelin was prepared by slow addition at room temperature with stirring, of calcium acetate to a diluted obelin solution (≈ 0.5 –1 mg/ml), both in 10 mM Bis-Tris buffer (pH 6.5), to a final Ca²⁺ concentration of 1 mM. During this procedure, a bright blue bioluminescence was observed. The Ca²⁺-discharged obelin displayed green fluorescence (8), indicating that the coelenteramide remains protein-bound because coelenteramide is not fluorescent in aqueous solution. The protein was concentrated to 26.6 mg/ml with Millipore centrifuge tubes.

Mutagenesis. Site-directed mutagenesis was done on the template pET19-OL8 expression plasmid (39) carrying the *O. longissima* wild-type apo-obelin. The Y138F mutation was carried out with the QuikChange site-directed mutagenesis kit (Stratagene) using the 5'-CGAATGGAAAGCTTTTGGAAAAATCTCTG-3' (forward) and 5'-CAGAGATTTTCCAAAAGCTT-TCCATTCG-3' (reverse) oligonucleotides. The plasmids harboring mutations were verified by DNA sequencing. The mutant purification protocol was similar to that for the wild-type obelin (15). The bioluminescence spectrum was measured with an AMINCO spectrofluorimeter (Thermo Spectronic) as described (32).

Crystallography. Initial crystallization screening was carried out by the multiple robotic and other methods, as described (40, 41). The plates were incubated at 4°C for >1 month. One rod-shaped single crystal was grown with 2% polyethylene glycol 400/2.0 M ammonium sulfate/0.1 M Hepes-Na, pH 7.5 (Crystal Screen, Hampton Research). The crystal was cut into three pieces of equal sizes (0.07 × 0.08 × 0.1 mm). Each part was picked up from the crystallization drop using a fiber loop and immersed for 3 s into a 1- μ l drop of a 3:1 mixture of well solution and 100% glycerol (42). Still in the loop, it was dragged along the surface

of a microscopic cover slide to remove excess liquid and flash-frozen in liquid nitrogen before the data collection process (43).

Data were collected at 0.9725-Å wavelength at beamline 22-ID (SER-CAT) at the Advanced Photon Source (APS) using a MAR 300 charge-coupled device detector at a 150-mm crystal-to-detector distance. A single sweep of 360 1.0° oscillation images was recorded with 2-s exposure time per frame. Diffraction data were indexed, integrated, and scaled (Table 2) using the HKL2000 software suite (44). Phases were determined with the molecular replacement program MOLREP (45) in CCP4 (46, 47) using Ca²⁺-loaded apo-obelin from *O. longissima* [Protein Data Bank (PDB) ID code 1SL7] as a search model. There is one molecule per asymmetric unit. Automated tracing was performed by using the initial model phases and the program ARP/WARP (48). The final model was obtained after several cycles of manual adjustment of the autotraced model using XFIT

(49), followed by restrained refinement with REFMAC5 (50). The electron density of coelenteramide was clearly visible in the center of the protein molecule. The final refinement statistics are shown in Table 2. The validation was performed with the MOLPROBITY online tool (51, 52). The coordinates were deposited in the PDB (53) with an access code 2F8P.

This work was supported by Russian Foundation for Basic Research Grant 05-04-48271, the "Molecular and Cellular Biology" program of the Russian Academy of Sciences, and the University of Georgia Research Foundation and the Georgia Research Alliance. The data were collected at Southeast Regional Collaborative Access Team (SER-CAT) 22-ID beamline at the Advanced Photon Source, Argonne National Laboratory. Use of the Advanced Photon Source was supported by the U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences, under Contract W-31-109-Eng-38.

- Morin, J. G. (1974) in *Coelenterate Biology: Reviews and New Perspectives*, eds. Muscatine, L. & Lenhoff, H. M. (Academic, New York), pp. 397–438.
- Shimomura, O., Johnson, F. H. & Saiga, Y. (1962) *J. Cell. Comp. Physiol.* **59**, 223–239.
- Shimomura, O. (1985) *Symp. Soc. Exp. Biol.* **39**, 351–372.
- Morin, J. G. & Hastings, J. W. (1971) *J. Cell. Physiol.* **77**, 305–312.
- Campbell, A. K. (1974) *Biochem. J.* **143**, 411–418.
- Charbonneau, H., Walsh, K. A., McCann, R. O., Prendergast, F. G., Cormier, M. J. & Vanaman, T. C. (1985) *Biochemistry* **24**, 6762–6771.
- Tsujii, F. I., Ohmiya, Y., Fagan, T. F., Toh, H. & Inouye, S. (1995) *Photochem. Photobiol.* **62**, 657–661.
- Markova, S. V., Vysotski, E. S., Blinks, J. R., Burakova, L. P., Wang, B.-C. & Lee, J. (2002) *Biochemistry* **41**, 2227–2236.
- Hermann, A. & Cox, J. A. (1995) *Comp. Biochem. Physiol. B* **111**, 337–345.
- Hastings, J. W. & Gibson, Q. H. (1963) *J. Biol. Chem.* **238**, 2537–2554.
- Shimomura, O. & Johnson, F. H. (1972) *Biochemistry* **11**, 1602–1608.
- Cormier, M. J., Hori, K., Karkhanis, Y. D., Anderson, J. M., Wampler, J. E., Morin, J. G. & Hastings, J. W. (1973) *J. Cell. Physiol.* **81**, 291–297.
- Vysotski, E. S. & Lee, J. (2004) *Acc. Chem. Res.* **37**, 405–415.
- Head, J. F., Inouye, S., Teranishi, K. & Shimomura, O. (2000) *Nature* **405**, 372–376.
- Liu, Z.-J., Vysotski, E. S., Chen, C.-J., Rose, J., Lee, J. & Wang, B.-C. (2000) *Protein Sci.* **9**, 2085–2093.
- Lee, J., Glushka, J. N., Markova, S. V. & Vysotski, E. S. (2001) in *Bioluminescence & Chemiluminescence 2000*, eds. Case, J. F., Herring, P. J., Robison, B. H., Haddock, S. H. D., Kricka, L. J. & Stanley, P. E. (World Scientific, Singapore), pp. 99–102.
- Deng, L., Markova, S. V., Vysotski, E. S., Liu, Z.-J., Lee, J., Rose, J. & Wang, B.-C. (2004) *J. Biol. Chem.* **279**, 33647–33652.
- Deng, L., Vysotski, E. S., Markova, S. V., Liu, Z.-J., Lee, J., Rose, J. & Wang, B.-C. (2005) *Protein Sci.* **14**, 663–675.
- Fisher, A. J., Raushel, F. M., Baldwin, T. O. & Rayment, I. (1995) *Biochemistry* **34**, 6581–6586.
- Conti, E., Franks, N. P. & Brick, P. (1996) *Structure (London)* **4**, 287–298.
- Schultz, L. W., Liu, L., Cegielski, M. & Hastings, J. W. (2005) *Proc. Natl. Acad. Sci. USA* **102**, 1378–1383.
- Bhattacharya, S., Bunick, C. G. & Chazin, W. J. (2004) *Biochim. Biophys. Acta* **1742**, 69–79.
- Watkins, N. J. & Campbell, A. K. (1993) *Biochem. J.* **292**, 181–185.
- Shimomura, O. & Johnson, J. F. (1970) *Nature* **227**, 1356–1357.
- Strynadka, N. C. & James, M. N. (1994) in *Encyclopedia of Inorganic Chemistry*, ed. King, R. B. (Wiley, New York), pp. 477–507.
- Ohmiya, Y. & Tsujii, F. I. (1993) *FEBS Lett.* **320**, 267–270.
- Nelson, M. R. & Chazin, W. J. (1998) *Biometals* **11**, 297–318.
- Usami, K. & Isobe, M. (1996) *Tetrahedron* **52**, 12061–12090.
- Shimomura, O. & Teranishi, K. (2000) *Luminescence* **15**, 51–58.
- Imai, Y., Shibata, T., Maki, S., Niwa, H., Ohashi, M. & Hirano, T. (2001) *Photochem. Photobiol. A* **146**, 95–107.
- Ohmiya, Y., Ohashi, M. & Tsujii, F. I. (1992) *FEBS Lett.* **301**, 197–201.
- Malikova, N. P., Stepanyuk, G. A., Frank, L. A., Markova, S. V., Vysotski, E. S. & Lee, J. (2003) *FEBS Lett.* **554**, 184–188.
- Deng, L., Vysotski, E. S., Liu, Z.-J., Markova, S. V., Malikova, N. P., Lee, J., Rose, J. & Wang, B.-C. (2001) *FEBS Lett.* **506**, 281–285.
- Vysotski, E. S., Liu, Z.-J., Markova, S. V., Blinks, J. R., Deng, L., Frank, L. A., Herko, M., Malikova, N. P., Rose, J. P., Wang, B.-C. & Lee, J. (2003) *Biochemistry* **42**, 6013–6024.
- McCapra, F. & Chang, Y. C. (1967) *Chem. Commun.* **19**, 1011–1012.
- Stepanyuk, G. A., Golz, S., Markova, S. V., Frank, L. A., Lee, J. & Vysotski, E. S. (2005) *FEBS Lett.* **579**, 1008–1014.
- Hori, K., Charbonneau, H., Hart, R. C. & Cormier, M. J. (1977) *Proc. Natl. Acad. Sci. USA* **74**, 4285–4287.
- Markova, S. V., Golz, S., Frank, L. A., Kalthof, B. & Vysotski, E. S. (2004) *J. Biol. Chem.* **279**, 3212–3217.
- Markova, S. V., Vysotski, E. S. & Lee, J. (2001) in *Bioluminescence & Chemiluminescence 2000*, eds. Case, J. F., Herring, P. J., Robison, B. H., Haddock, S. H. D., Kricka, L. J. & Stanley, P. E. (World Scientific, Singapore), pp. 115–118.
- Liu, Z. J., Tempel, W., Ng, J. D., Lin, D., Shah, A. K., Chen, L., Horanyi, P. S., Habel, J. E., Kataeva, I. A., Xu, H., et al. (2005) *Acta Crystallogr. D* **61**, 679–684.
- Shah, A. K., Liu, Z. J., Stewart, P. D., Schubot, F. D., Rose, J. P., Newton, M. G. & Wang, B. C. (2005) *Acta Crystallogr. D* **61**, 123–129.
- Teng, T. Y. (1990) *J. Appl. Crystallogr.* **23**, 387–391.
- Hope, H. (1988) *Acta Crystallogr. D* **44**, 22–26.
- Otwinowski, Z. & Minor, W. (1997) *Methods Enzymol.* **276**, 307–326.
- Vagin, A. & Teplyakov, A. (1997) *J. Appl. Cryst.* **30**, 1022–1025.
- Potterton, E., Briggs, P., Turkentburg, M. & Dodson, E. (2003) *Acta Crystallogr. D* **59**, 1131–1137.
- Winn, M. D. (2003) *J. Synchrotron Radiation* **10**, 23–25.
- Perrakis, A., Morris, R. & Lamzin, V. S. (1999) *Nat. Struct. Biol.* **6**, 458–463.
- McRee, D. E. (1999) *J. Struct. Biol.* **125**, 156–165.
- Murshudov, G. N., Vagin, A. A. & Dodson, E. J. (1997) *Acta Crystallogr. D* **53**, 240–255.
- Lovell, S. C., Davis, I. W., Arendall, W. B., III, de Bakker, P. I. W., Word, J. M., Prisant, M. G., Richardson, J. S. & Richardson, D. C. (2003) *Proteins* **50**, 437–450.
- Richardson, J. S. (2003) *Methods Biochem. Anal.* **44**, 305–320.
- Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissing, H., Shindyalov, I. N. & Bourne, P. E. (2000) *Nucleic Acids Res.* **28**, 235–242.